Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | BLK | P51451 | 1/20 | 0.63 |
| ▸ | BMX | P51813 | 1/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | BTK | Q06187 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27522925 | 0.91 | EGFR (0.70) | EGFRERBB2ABCG2AURKARPS6KB1 | |
| SCHEMBL7161985 | 0.89 | EGFR (0.64) | EGFRERBB2KDM4EERBB4ABCG2 | |
| SCHEMBL6273052 | 0.88 | EGFR (0.70) | EGFRERBB2KDM4EERBB4ABCG2 | |
| SCHEMBL30512 | 0.86 | EGFR (0.66) | EGFRERBB2KDM4EABCG2FYN | |
| SCHEMBL2990711 | 0.85 | EGFR (0.72) | EGFRERBB2KDM4EERBB4FYN | |
| SCHEMBL8430952 | 0.84 | KDM4E (0.60) | EGFRERBB2KDM4EERBB4FYN | |
| SCHEMBL8430944 | 0.84 | KDM4E (0.60) | EGFRERBB2KDM4EERBB4FYN | |
| SCHEMBL8434635 | 0.84 | KDM4E (0.60) | EGFRERBB2KDM4EERBB4FYN | |
| SCHEMBL31060998 | 0.82 | EGFR (1.00) | EGFRERBB2ABCG2 | |
| SCHEMBL1417740 | 0.82 | EGFR (1.00) | EGFRERBB2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| CN-1370535-A | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | claimed |
| CN-1194692-C | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2005-03-30 | — | — | CN | disclosed |
| CN-1370535-A | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885KDM4E 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.